HOME >> BIOLOGY >> TECHNOLOGY |
New Drugs on the Horizon Session Highlights New Small Molecule Drug
Candidates
ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical and mechanism of action data for its selective kinase inhibitor, ENMD-2076. On Sunday, April 13, 2008, Mark R. Bray, Ph.D., Vice President, Research, gave an oral presentation during the "New Drugs on the Horizon 2" symposium at the American Association for Cancer Research (AACR) Annual Meeting being held this week in San Diego, California.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
During the presentation, Dr. Bray highlighted ENMD-2076's unique combination of antiangiogenic, cell cycle, and antiproliferative activities. In preclinical studies, ENMD-2076 demonstrated potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. ENMD-2076 is an orally active, multi-kinase inhibitor that has shown an acceptable toxicity profile in multiple preclinical studies without cardiovascular effects.
Dr. Bray commented on the presentation, "We are fortunate to have been selected to showcase the potent activity of ENMD-2076 during this high profile session. ENMD-2076 is an exciting compound with demonstrated single-agent activity against a broad range of tumor types. EntreMed recently commenced a Phase 1, dose-escalation study with ENMD-2076 in advanced cancers and plans to initiate a second Phase 1 study in hematological cancers later in 2008."
To view a copy of Dr. Bray's presentation, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at http://www.entremed.com.
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act with respect to the outlook
for expectations for future financial or business performance (including
the timing of royalty revenues and future R&D expenditures), strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made, and no
duty to update forward-looking statements is assumed. Actual results could
differ materially from those currently anticipated due to a number of
factors, including those set forth in Securities and Exchange Commission
filings under "Risk Factors," including risks relating to the need for
additional capital and the uncertainty of additional funding; variations in
actual sales of Thalomid(R), risks associated with the Company's product
candidates; the early-stage products under development; results in
preclinical models are not necessarily indicative of clinical results,
uncertainties relating to preclinical and clinical trials; success in the
clinical development of any products; dependence on third parties; future
capital needs; and risks relating to the commercialization, if any, of the
Company's proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).
CONTACT:
Ginny Dunn
Associate Director, Corporate
Communications & Investor Relations
EntreMed, Inc.
240.864.264
SOURCE EntreMed, Inc. Copyright©2008 PR Newswire. All rights reserved |